NIKKEI 225
39,026.33 +409.23 (+1.06%) HANG SENG
18,854.07 -341.53 (-1.78%) CRUDE OIL
76.94 -0.63 (-0.81%) GOLD FUTURES
2,367.70 -25.20 (-1.05%) DOW
39,671.04 -201.95 (-0.51%) Bitcoin GBP
54,542.00 -337.17 (-0.61%)
Bio-Techne Corporation (TE1.F)
| Previous close | 76.00 |
| Open | 75.50 |
| Bid | 76.00 x N/A |
| Ask | 76.50 x N/A |
| Day's range | 75.50 - 76.50 |
| 52-week range | 49.40 - 80.50 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 12.055B |
| Beta (5Y monthly) | 1.23 |
| PE ratio (TTM) | 65.95 |
| EPS (TTM) | 1.16 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | 0.30 (0.39%) |
| Ex-dividend date | 10 May 2024 |
| 1y target est | 549.60 |
PR NewswireBIO-TECHNE HIGHLIGHTS RECENTLY ANNOUNCED TOP-LINE BIOMARKER DATA FROM PARTNER, REGULUS THERAPEUTICS, USING THE COMPANY'S PROPRIETARY TECHNOLOGY
Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced continued technical and clinical collaboration following release of Regulus' positive topline results from the second cohort of patients in its Phase 1b MAD (multiple ascending dose) study of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). The two companies began t
Insider MonkeyBio-Techne Corporation (TECH) Declined on Weak Q4 Results
Baron Funds, an investment management company, released its “Baron Asset Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded here. US markets continued its strong rally in the first quarter. Robust economic data and relatively strong corporate earnings boosted the rally along with the anticipation of a soft landing of […]
Simply Wall St.Bio-Techne Third Quarter 2024 Earnings: Beats Expectations
Bio-Techne ( NASDAQ:TECH ) Third Quarter 2024 Results Key Financial Results Revenue: US$303.4m (up 3.2% from 3Q 2023...
